Compare PANL & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PANL | AQST |
|---|---|---|
| Founded | 1996 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 485.4M | 529.4M |
| IPO Year | 2015 | 2007 |
| Metric | PANL | AQST |
|---|---|---|
| Price | $8.06 | $5.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $9.00 | $9.00 |
| AVG Volume (30 Days) | 367.1K | ★ 3.7M |
| Earning Date | 05-08-2026 | 05-01-2026 |
| Dividend Yield | ★ 2.63% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $385,088,209.00 | $67,430,000.00 |
| Revenue This Year | $0.72 | $10.08 |
| Revenue Next Year | N/A | $49.60 |
| P/E Ratio | $21.94 | ★ N/A |
| Revenue Growth | N/A | ★ 0.77 |
| 52 Week Low | $4.56 | $2.94 |
| 52 Week High | $9.39 | $7.55 |
| Indicator | PANL | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 58.77 | 66.71 |
| Support Level | $7.99 | $3.70 |
| Resistance Level | $9.16 | $5.10 |
| Average True Range (ATR) | 0.27 | 0.28 |
| MACD | 0.04 | 0.10 |
| Stochastic Oscillator | 82.58 | 76.04 |
Pangaea Logistics Solutions Ltd and its subsidiaries collectively, Pangaea or the Company, provide seaborne drybulk logistics and transportation services as well as terminal and stevedoring services. Pangaea utilizes its logistics expertise to service a broad base of industrial customers who require the transportation of a wide variety of dry bulk cargoes, including grains, coal, iron ore, pig iron, hot briquetted iron, bauxite, alumina, cement clinker, dolomite, and limestone. The Company's operating segments include the shipping segment: The Company's operating segments include the shipping segment and six terminal and stevedoring operating segments. The company operates in the USA, Germany, Canada, Singapore, the United Kingdom, and other countries, with maximum from the USA and others.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.